Advanced clinical states in prostate cancer.
The classification of clinical disease states within advanced prostate cancer is set apart from other solid tumors largely through measurement of prostate-specific antigen in the blood. This testing has allowed the distinction between the castration-sensitive and the castration-resistant states, to complement radiographic distinction within advanced prostate cancer. This has paved the way for advances in prognostication and treatment of patients within a heterogeneous disease group. Currently used clinical classifications have limitations and continue to evolve. The authors define the current disease states and discuss implications for prognosis and treatment decisions, as well as the limitations of existing classifications and emerging discoveries.
Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA 98109, USA. hhcheng@u.washington.edu
Heather H
HH
Cheng
Daniel W
DW
Lin
Evan Y
EY
Yu
D000726:Androgen Antagonists / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary; D019496:Cancer Vaccines / Q000627:therapeutic use; D018450:Disease Progression; D000077143:Docetaxel; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local; D009376:Neoplasms, Hormone-Dependent / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D009919:Orchiectomy; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D043823:Taxoids / Q000627:therapeutic use; D014020:Tissue Extracts / Q000627:therapeutic use
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D043823:Taxoids; D014020:Tissue Extracts; D000077143:Docetaxel; D007987:Gonadotropin-Releasing Hormone; C511774:sipuleucel-T; D017430:Prostate-Specific Antigen